Neuromyelitis optica treatment: analysis of 36 patients. - Wikidata - wikimedia - TriplyDB

Neuromyelitis optica treatment: analysis of 36 patients.

Neuromyelitis optica treatment: analysis of 36 patients.

http://www.wikidata.org/entity/Q33691185

about

Therapy of NMO spectrum disorders Immunology of neuromyelitis optica: a T cell-B cell collaboration Treatment of neuromyelitis optica: state-of-the-art and emerging therapies Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder Update on neuromyelitis optica: natural history and management.The treatment of neuromyelitis optica.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.Neuromyelitis optica: an antibody-mediated disorder of the central nervous system.Current options for the treatment of optic neuritis.Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Treatment of Neuromyelitis Optica: Review and Recommendations.The differential diagnosis of longitudinally extensive transverse myelitis.Treatment of neuromyelitis optica: an evidence based review.The spectrum of neuromyelitis optica (NMO) in childhood.A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.Therapeutic options in neuromyelitis optica spectrum disorders.Neuromyelitis optica and pregnancy.Neuromyelitis Optica (Devic's Syndrome): an Appraisal.From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.The profile of patients followed at the Neuroimmunology Clinic at UNIFESP: 20 years analysis.Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.Lack of response to monoclonal antibody therapy in neuromyelitis optica.[Therapeutic options for autoimmune encephalomyelitis].Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease.Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica.Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.Devic's disease in an adolescent girl with juvenile dermatomyositis.Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies.Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints.Seasonality of 278 neuromyelitis optica relapses in a Brazilian cohort.

P2860

Q26779910-09117219-FE26-4C9B-932E-3EA321E10651 Q27016045-8A1C5F40-9D9B-4B4F-8109-A29B22407AF9 Q28245749-7016E192-64B7-4CD0-BA2E-2C6DD0519AD2 Q30577078-A9BA0F08-C018-4CF2-A63D-2568A4BAD0C1 Q30676331-EEA69E42-6270-476C-A62F-A361881FA54B Q30785267-3A7F9A22-83AD-458C-84BE-F56B0A7156F8 Q33678297-B8CFA327-8B6D-4300-8438-63DA9A2668FB Q33702126-C1573B46-C17A-4F96-AD4E-42E5F32DB417 Q34399291-44667D7F-03B7-4272-A8D6-54C18EFB04D0 Q35052199-9478B03E-FD60-40BF-A683-5DE367113BE3 Q35072715-03E91B81-EE56-468B-91BB-3102ED67F8BF Q35738898-AF8C52B3-5E43-439F-9F2C-98A099E54C94 Q36173222-04615930-571F-4D2A-B924-895500404774 Q36484394-53616D0E-3F94-4ECB-B9E7-1DE8F190FCF4 Q36648907-210F0077-F7BD-4F8A-B40A-1429807A139D Q37588037-BD730854-1E55-40B5-85E8-189D39762DAE Q37888959-803FCA71-5F2E-4E11-976C-086ECC0DA24C Q37973248-A0A1B855-EB1E-44A8-A979-AE4FFE036886 Q38031816-902C7B9C-DE46-4624-9F66-EBA585D47332 Q38074625-EFD515F8-211D-4459-A8FD-68473CB8AB76 Q38197504-28E13A08-3F5D-44B1-83AE-C9AA28836A6C Q38721559-BC41E6EA-0837-468F-B9FB-7491FCB0D408 Q38866313-CA9589E9-64D2-4C11-95EE-EDFA1FABF3D0 Q38893206-AED882CC-00C6-4EF0-B434-476F43ED4012 Q39032639-C1394CE6-57F5-4D0C-B443-C4DC4AE21FAA Q40920201-5CBFFA3C-550C-4C9C-8D75-39D930A367F8 Q41096503-6F1DDE39-A30D-408F-BB00-A18A3F51442C Q41626170-06E087B0-6838-47CF-B8B5-4664A9518921 Q42345824-9DF435B7-BBD5-44E2-94B5-89B41D0CAF66 Q43607388-147ADBE3-E01C-4AE8-B224-980960C9E0A6 Q43752309-CE3544B7-9D73-46F3-AAD0-963E8661C1D2 Q45832517-D72A1409-969C-4EE3-9A8D-C1EC90CDE49D Q48198452-9663CBC0-2F73-449A-AF87-110E2FEC3739 Q50075756-CD06BE2E-B24D-41A7-8D7A-309B89EF013E Q51189376-61E7741C-3327-40FD-9F7E-3619AC874F7E Q53125112-36FCB37F-6A33-40AD-920D-EB2D8877161C Q53214289-C2ACB30A-CD5E-4B6E-BBFB-001996C24CF4 Q53588537-9FEA9E65-566B-44BF-8715-89DD0CE649BD

P2860

Neuromyelitis optica treatment: analysis of 36 patients.

http://www.wikidata.org/entity/Q33691185

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Neuromyelitis optica treatment: analysis of 36 patients.

@ast

Neuromyelitis optica treatment: analysis of 36 patients.

@en

type

label

Neuromyelitis optica treatment: analysis of 36 patients.

@ast

Neuromyelitis optica treatment: analysis of 36 patients.

@en

prefLabel

Neuromyelitis optica treatment: analysis of 36 patients.

@ast

Neuromyelitis optica treatment: analysis of 36 patients.

@en

P1433

Q33691185-DC6605E1-60BF-4A03-8D56-5CCAF580BE72

P1476

Q33691185-D8E82DAF-3C09-4267-A59F-3139CD3E87D6

P2093

Q33691185-42BEAC90-7E64-4464-9916-ABB83B9626AA

Q33691185-AB5DD62D-25D9-4ECC-A8E2-2653C71FCA47

Q33691185-AD209661-BC79-4D71-9265-947015A71A4E

Q33691185-B1BE1EFE-9EDC-4811-89D0-205C90792E89

Q33691185-F73DE640-D81A-44BA-98DB-003FA4AB38CB

P304

Q33691185-67143D8A-9FB3-4FBA-B6DE-6BEAEB4CE720

P31

Q33691185-4ED4372C-4D62-418C-85F5-7DC77A7C59F4

P356

Q33691185-5FD8C0AD-7E39-4F5E-8333-D7C38EF105FE

P433

Q33691185-64C7CECC-7078-4449-868C-E5558360A27B

P478

Q33691185-C746784B-516B-4409-B220-453D170E71B8

P577

Q33691185-C1B99F2E-0C21-4CB7-9C5C-82CBBE672297

P698

Q33691185-9B5A9B0B-0DEC-4DB0-B1A9-BEAF1927A379

P356

ARCHNEUROL.2010.203

P1433

P1476

Neuromyelitis optica treatment: analysis of 36 patients.

@en

P2093

Alberto Alain Gabbai

http://www.w3.org/2001/XMLSchema#string

Daniel May Oliveira

http://www.w3.org/2001/XMLSchema#string

Denis Bernardi Bichuetti

http://www.w3.org/2001/XMLSchema#string

Enedina Maria Lobato de Oliveira

http://www.w3.org/2001/XMLSchema#string

Nilton Amorin de Souza

http://www.w3.org/2001/XMLSchema#string

P304

1131-1136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUROL.2010.203

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20837859

http://www.w3.org/2001/XMLSchema#string